Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2010

View Archived Issues

GW-5074 has therapeutic activity in mouse model of Parkinson's disease

Phase II data on MK-0941 cast doubt on suitability for treatment of diabetes

Progenics Pharma advances phase III trial of Relistor for opioid-induced constipation

Imeglimin shows promise in phase II trials in type 2 diabetes

Phase I data presented on flu vaccine NB-1008 and acne therapy NB-003

CYT-003-QbG-10 is safe and efficacious in allergic asthma

SUN-13834 is efficacious in patients with atopic dermatitis

NCI selects Bexion to collaborate on cancer nanotherapeutic SapC-DOPS

Cel-Sci receives Russian approval for phase III Multikine trial

CHMP recommends approval of AstraZeneca's ticagrelor

Octapharma now withdrawing all lots of Octagam from U.S. market

Chelsea Therapeutics begins phase II CH-4051 trial in rheumatoid arthritis

Novartis' H5N1 vaccine Aflunov for adults gets positive opinion in E.U.

FDA approves phase Ib ibudilast trial in methamphetamine-dependent subjects

Actelion reports on CONSCIOUS-2 phase II trial of clazosentan in aSAH

AMT-080 receives FDA orphan drug status for Duchenne's muscular dystrophy

EP-1300 epitope-based DNA vaccine for malaria enters phase I

Pivotal trial data reported on brentuximab vedotin in Hodgkin's lymphoma

Advanced Targeting Systems receives NIH award to advance SP-SAP to clinic

Short-acting anesthetic/sedative remimazolam completes phase IIb trial

Nycomed submits European filing for marketing approval of EX-101

Studies point to potential benefit of ITI-007 in Parkinson's disease

GlaxoSmithKline claims new I-kappa-kinase beta inhibitors

Novel phosphatidylinositol 3-kinase inhibitors described

Gruenenthal discloses new voltage-gated K(V)7.2/3 potassium channel activators

Vanderbilt University claims novel GlyT-1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.